2C-B

Common Names: Bromo-2, Nexus, Bromo, Mescaline, BDMPEA

Psychoactive Effects

Positive Effects

  • Euphoria
  • Pleasure

Neutral Effects

  • Visual hallucinations
  • Time distortion
  • Enhanced colors
  • Geometric patterns
  • Altered body perception
  • Enhanced tactile sensations

Negative Effects

  • Anxiety
  • Paranoia

Dosage Guidelines

Route Threshold Light Common Strong Heavy
Oral 2-5 mg 5-15 mg 15-25 mg 25-40 mg 40+ mg
Insufflated 1-3 mg 3-8 mg 8-15 mg 15-25 mg 25+ mg

Duration

Phase Duration
Onset 30-60 minutes
Peak 2-4 hours
Total 4-8 hours
After effects 2-4 hours

Pharmacology

Mechanism of Action: 2C-B acts as a partial agonist at serotonin 5-HT2A and 5-HT2C receptors, with some activity at 5-HT2B receptors. It also has weak affinity for dopamine D2 receptors.

Metabolism: Metabolized in the liver primarily by CYP2D6 and CYP2C19 enzymes. Major metabolites include 4-bromo-2,5-dimethoxyphenethylamine and various hydroxylated derivatives.

Half-life: Approximately 2-4 hours, with effects typically lasting 4-8 hours.

Bioavailability: ~70% when taken orally, with peak plasma concentrations reached within 1-2 hours.

Risks and Harm Reduction

AddictionToxicityDependenceOverdose

⚠️ Important: Always practice harm reduction. Start with low doses, test your substances, and ensure a safe set and setting. Never use alone.

Legal Status

Disclaimer: Legal status varies by jurisdiction and may change. This information is for educational purposes only.

References

  • • Shulgin, A. T., & Shulgin, A. (1991). PiHKAL: A Chemical Love Story. Transform Press.
  • • Glennon, R. A., et al. (1994). 2C-B: A new psychoactive phenylethylamine. Journal of Medicinal Chemistry, 37(8), 1056-1060.
  • • de la Torre, R., et al. (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Therapeutic Drug Monitoring, 26(2), 137-144.
  • • Rickli, A., et al. (2016). Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology, 99, 546-553.
  • • Information compiled from PsychonautWiki